Publisher
MJS Publishing, Medical Journals Sweden AB
Reference21 articles.
1. IARC. Data visualization tools for exploring the global cancer burden in 2020 [Internet]. [cited 22-12-2023].Available from: https://gco.iarc.fr/today/home
2. ASCO. Prostate cancer: statistics [Internet]. [cited 22-12-2023]. Available from: https://www.cancer.net/cancer-types/prostate-cancer/statistics
3. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322
4. Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA approval summary: Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29(9):1651–57. https://doi.org/10.1158/1078-0432.CCR-22-2875
5. EMA [Internet]. [cited 18-04-2024]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto